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TRACHOMA CONTROL
Don’t letmisinformation derail the trachoma elimination
programme
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Chisholm and colleagues’ paper is important to policy makers,1
so serious errors in the trachoma analysis require correction.2
Firstly, “mass treatment with azithromycin” for trachoma was
defined as azithromycin treatment for all children aged 1-10
years,3 whereas the World Health Organization recommends
treatment of all residents.
Secondly, data from a 1998-9 western Nepal trial were
extrapolated to estimate effectiveness of mass treatment
throughout sub-Saharan Africa and South East Asia.
Thirdly, the model’s coverage level parameter “does not affect
the reduction in the prevalence of active trachoma”3; we doubt
that this is true.
Fourthly, disability weights were assigned only for the outcomes
visual impairment and blindness.3 Trichiasis has considerable
physical, social, and economic effects from its onset, not just
after low vision ensues. Furthermore, active trachoma was
denied a disability weight, and the ancillary savings in disability
adjusted life years (DALYs) of mass azithromycin treatment
(which may include reduced all cause mortality in children4)
were ignored.
Fifthly,WHO and partners aim to eliminate trachoma as a public
health problem by 2020. An elimination programme derives
positive externalities (in economic terms) from protection of
future generations. It is a mistake to assess infectious diseases
in the same way that cataract is assessed.
Lastly, costs were assigned for azithromycin purchase using a
theoretical price.2Azithromycin for trachoma control is donated
by the manufacturer.
On the basis of analyses that are flawed on both sides of the
cost effectiveness equation, Chisholm and colleagues concluded
that saving a DALY with mass azithromycin treatment in
trachoma endemic areas of sub-Saharan Africa or South East
Asia costs more than the per capita gross domestic product of
each region. International commitment to trachoma control has
never been stronger,5 and it would be tragic for poor
communities affected by trachoma if programme momentum
was lost through misinformation.
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